Oxytrol: Overactive Bladder Relief with Continuous Delivery
Oxytrol
| Product dosage: 5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.63 | $49.00 (0%) | 🛒 Add to cart |
| 60 | $1.42 | $98.00 $85.00 (13%) | 🛒 Add to cart |
| 90 | $1.33 | $147.00 $120.00 (18%) | 🛒 Add to cart |
| 120 | $1.30 | $196.00 $156.00 (20%) | 🛒 Add to cart |
| 180 | $1.26 | $294.00 $226.00 (23%) | 🛒 Add to cart |
| 270 | $1.23 | $441.00 $331.00 (25%) | 🛒 Add to cart |
| 360 | $1.22
Best per pill | $588.00 $438.00 (26%) | 🛒 Add to cart |
Synonyms
| |||
Oxytrol is a transdermal system designed for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency. It delivers oxybutynin, an antispasmodic anticholinergic agent, through the skin for consistent, controlled release over a 3- to 4-day period. This method bypasses first-pass metabolism, potentially reducing systemic side effects while maintaining therapeutic efficacy. It is indicated for adults who require a non-oral option due to tolerability or compliance concerns.
Features
- Transdermal delivery system providing continuous release of oxybutynin
- Each patch contains 36 mg of oxybutynin, delivering 3.9 mg per day
- Water-resistant adhesive for secure wear during bathing or light exercise
- Applied twice weekly (every 3–4 days) for consistent symptom control
- Available by prescription in standardized dosing
Benefits
- Reduces episodes of urge incontinence and urinary frequency
- Maintains stable plasma concentrations, minimizing peak-trough fluctuations
- Avoids gastrointestinal metabolism, potentially lowering incidence of dry mouth
- Convenient dosing schedule improves adherence compared to daily oral regimens
- Discreet, low-profile wear enhances patient comfort and lifestyle flexibility
- Provides localized action with systemic efficacy for targeted symptom relief
Common use
Oxytrol is primarily prescribed for the management of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. It is suitable for patients who have experienced side effects with oral anticholinergics or prefer a transdermal delivery system. It may also be considered for individuals with difficulty swallowing or those seeking a simplified dosing regimen. Clinical use is generally reserved for adults who have not achieved satisfactory control with behavioral modifications alone.
Dosage and direction
Apply one Oxytrol patch to clean, dry, intact skin on the abdomen, hip, or buttock twice weekly (every 3–4 days). Rotate application sites to avoid skin irritation; do not apply to the same site within 7 days. Ensure the skin is free of oils, lotions, or powders before application. Press firmly for 30 seconds to ensure adhesion, especially around the edges. Replace with a new patch on the scheduled day, even if the previous patch remains adherent. Do not cut the patch.
Precautions
Avoid exposure of application site to external heat sources (e.g., heating pads, prolonged direct sunlight), as increased absorption may occur. Monitor for signs of urinary retention in patients with clinically significant bladder outlet obstruction. Use with caution in patients with gastrointestinal obstructive disorders, such as pyloric stenosis, due to anticholinergic effects. May cause drowsiness or blurred vision; advise patients to exercise caution when driving or operating machinery. Elderly patients may be more susceptible to anticholinergic central nervous system effects.
Contraindications
Oxytrol is contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma. It should not be used in individuals with known hypersensitivity to oxybutynin or any component of the patch adhesive system. Avoid use in patients with myasthenia gravis or severe ulcerative colitis. Contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.
Possible side effects
Common side effects include application site reactions (pruritus, erythema, rash), dry mouth, constipation, and drowsiness. Less frequently reported effects include blurred vision, dizziness, urinary hesitation, and gastrointestinal discomfort. Systemic anticholinergic effects such as tachycardia, flushing, or heat prostration may occur. Severe but rare adverse reactions include angioedema, anaphylaxis, and central nervous system effects such as hallucinations or agitation. Discontinuation should be considered if severe dermatitis or generalized skin reactions develop.
Drug interaction
Concomitant use with other anticholinergic agents may enhance therapeutic and adverse effects. Monoamine oxidase inhibitors may intensify anticholinergic side effects. Use with caution alongside central nervous system depressants (e.g., benzodiazepines, opioids) due to additive sedative effects. Drugs that inhibit CYP3A4 (e.g., ketoconazole, itraconazole) may increase oxybutynin plasma concentrations. Anticholinergic effects may reduce gastrointestinal motility and affect absorption of other orally administered drugs.
Missed dose
Apply the missed patch as soon as remembered. If it is almost time for the next application, skip the missed dose and resume the regular schedule. Do not apply extra patches to make up for a missed dose. Maintain the twice-weekly (every 3–4 days) application routine without doubling up.
Overdose
Symptoms of overdose may include severe anticholinergic effects: central nervous system excitation (restlessness, tremor, irritability), hallucinations, respiratory depression, tachycardia, hypertension, and urinary retention. Manage with supportive care; activated charcoal may be administered if ingestion occurs. In severe cases, physostigmine may be considered for life-threatening symptoms under controlled medical supervision. Dialysis is not likely to be effective due to oxybutynin’s volume of distribution.
Storage
Store at room temperature (20–25°C or 68–77°F). Keep in original pouch until use. Protect from moisture and direct sunlight. Do not store outside the sealed protective pouch. Keep out of reach of children and pets. Do not freeze.
Disclaimer
This information is intended for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, changing, or discontinuing any medication. Individual patient needs and responses may vary. Only a licensed medical professional can determine the appropriate therapy based on clinical evaluation.
Reviews
Clinical studies demonstrate that Oxytrol provides significant reduction in weekly incontinence episodes and urinary frequency compared to placebo. Patient-reported outcomes often highlight improved quality of life and convenience of the transdermal system. Some users report mild to moderate application site reactions, though these frequently diminish with continued use or site rotation. Adherence rates are generally higher compared to oral anticholinergics due to the simplified twice-weekly dosing. Long-term users note sustained efficacy with stable side effect profiles when applied as directed.